[{"orgOrder":0,"company":"Amplicore","sponsor":"Photon Fund","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"AM3101","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amplicore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amplicore \/ Photon Fund","highestDevelopmentStatusID":"4","companyTruncated":"Amplicore \/ Photon Fund"}]

Find Clinical Drug Pipeline Developments & Deals by Amplicore

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CRS
                          Not Confirmed
                          CRS
                          Not Confirmed

                          Details : The proceeds from the financing will enable Amplicore to complete the preclinical development of its two leading products, AM3101 and AM1101, and position the company for the next round of financing.

                          Product Name : AM3101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 25, 2021

                          Lead Product(s) : AM3101

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Preclinical

                          Sponsor : Photon Fund

                          Deal Size : $4.0 million

                          Deal Type : Financing

                          blank